multimmune GmbH

..........delivering innovative cancer theranostics


Our Latest News and Updates are now collated on our Linkedin page.



Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer


Ex vivo Hsp70-activated NK cells in combination with PD-1 inhibition significantly increase overall survival in preclinical models of glioblastoma and lung cancer

Long-term control of lung cancer in patient treated with ENKASTIM NK cell therapy followed by second-line PD-1 inhibition

Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: A Clinical Phase I Trial

Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy – a case report

Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) – from preclinical studies to a clinical phase II trial 


Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody


Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme B

A novel expression and purification system for the production of enzymatic and biologically active human granzyme B.


Membrane Hsp70 - A novel target for the isolation of circulating tumor cells after Epithelial-to-Mesenchymal Transition

Dynamics of Heat Shock Protein 70 serum levels as a predictor of clinical response in non-small-cell lung cancer and correlation with the hypoxia-related marker osteopontin

Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer

Patient survival by Hsp70 membrane phenotype: association with different routes of metastasis

High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis

Quantitative analysis of liposomal heat shock protein 70 (Hsp70) in the blood of tumor patients using a novel LipHsp70 ELISA

Extracellular cell stress proteins as biomarkers of human disease

Hsp70 - a bimarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck

Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models

Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma


In vivo imaging of CT26 mouse tumours by using cmHsp70.1 monoclonal antibody.